2023
Isolation and Quarantine for Coronavirus Disease 2019 in the United States, 2020–2022
Oeltmann J, Vohra D, Matulewicz H, DeLuca N, Smith J, Couzens C, Lash R, Harvey B, Boyette M, Edwards A, Talboy P, Dubose O, Regan P, Loosier P, Caruso E, Katz D, Taylor M, Moonan P. Isolation and Quarantine for Coronavirus Disease 2019 in the United States, 2020–2022. Clinical Infectious Diseases 2023, 77: 212-219. PMID: 36947142, PMCID: PMC11094624, DOI: 10.1093/cid/ciad163.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019Case patientsDisease 2019Positive severe acute respiratory syndrome coronavirus 2 test resultAdult case patientsCase investigationCOVID-19Public health programsPublic health workforceHealth programsHealth workforceContact tracingPatientsHealth officialsMost adultsAdultsDaysImpact of contactRepresentative sampleTotalMore adultsPanel SurveyQuarantine
2017
Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa
Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa. Clinical Infectious Diseases 2017, 66: 1246-1253. PMID: 29293906, PMCID: PMC5888963, DOI: 10.1093/cid/cix1125.Peer-Reviewed Original ResearchConceptsCells/mm3Immunodeficiency virus coinfectionAntiretroviral therapyMDR tuberculosisCD4 countVirus coinfectionConcurrent treatmentTreatment outcomesHuman immunodeficiency virus (HIV) coinfectionUndetectable HIV viral loadConcurrent antiretroviral therapyMDR tuberculosis patientsHIV viral loadMultidrug-resistant tuberculosisStrong risk factorTuberculosis-HIVTuberculosis outcomesAdverse eventsTuberculosis patientsImproved survivalMedian agePrimary outcomeHIV statusViral loadCure rate